Inventor · disambiguated record
Simon Giroux
Also filed as: GIROUX SIMON
28 granted patents·17 pending applications·236 citations·filing 2010–2023
97Inventor score
Top patents by PatentIndex Score
45 records- 0198US9376448B2DNA-PK inhibitorsVERTEX PHARMA·Filed 2013·Granted Jun 28, 2016·46 cites·10 claims
- 0297US9925188B2DNA-PK inhibitors and uses thereofVERTEX PHARMA·Filed 2016·Granted Mar 27, 2018·24 cites·18 claims
- 0396US9592232B2DNA-PK inhibitorsVERTEX PHARMA·Filed 2014·Granted Mar 14, 2017·24 cites·13 claims
- 0495US9359380B2DNA-PK inhibitorsVERTEX PHARMA·Filed 2014·Granted Jun 7, 2016·19 cites·25 claims
- 0595US9340557B2Substituted quinoxaline DNA-PK inhibitorsVERTEX PHARMA·Filed 2014·Granted May 17, 2016·19 cites·26 claims
- 0695US9296701B2DNA-PK inhibitorsVERTEX PHARMA·Filed 2013·Granted Mar 29, 2016·21 cites·17 claims
- 0794US9878993B2DNA-PK inhibitors for treatment of cancerVERTEX PHARMA·Filed 2016·Granted Jan 30, 2018·10 cites·7 claims
- 0893US10786512B2DNA-PK inhibitorsVERTEX PHARMA·Filed 2019·Granted Sep 29, 2020·3 cites·8 claims
- 0992US10973830B2Substituted quinoxaline DNA-PK inhibitorsVERTEX PHARMA·Filed 2019·Granted Apr 13, 2021·3 cites·23 claims
- 1092US10076521B2DNA-PK inhibitorsVERTEX PHARMA·Filed 2017·Granted Sep 18, 2018·7 cites·21 claims
- 1191US11884672B2Modulators of alpha-1 antitrypsinVERTEX PHARMA·Filed 2020·Granted Jan 30, 2024·4 cites·11 claims
- 1291US10501439B2DNA-PK inhibitorsVERTEX PHARMA·Filed 2018·Granted Dec 10, 2019·5 cites·18 claims
- 1391US10442791B2DNA-PK inhibitorsVERTEX PHARMA·Filed 2018·Granted Oct 15, 2019·5 cites·13 claims
- 1491US10391095B2DNA-PK inhibitorsVERTEX PHARMA·Filed 2018·Granted Aug 27, 2019·5 cites·9 claims
- 1591US8471014B2Process of making gyrase and topoisomerase IV inhibitorsSHANNON DEAN·Filed 2012·Granted Jun 25, 2013·10 cites·24 claims
- 1690US9987284B2Substituted benzooxadiazole DNA-PK inhibitorsVERTEX PHARMA·Filed 2016·Granted Jun 5, 2018·5 cites·23 claims
- 1789US12331057B2Modulators of alpha-1 antitrypsinVERTEX PHARMA·Filed 2023·Granted Jun 17, 2025·1 cites·11 claims
- 1889US10258627B2DNA-PK inhibitorsVERTEX PHARMA·Filed 2017·Granted Apr 16, 2019·4 cites·19 claims
- 1986US12251387B2Substituted quinoxalines and benzo[c][1,2,5]oxadiazoles as DNA-PK inhibitorsVERTEX PHARMA·Filed 2023·Granted Mar 18, 2025·0 cites·20 claims
- 2086US8354419B2Benzimidazole analogues for the treatment or prevention of flavivirus infectionsVERTEX PHARMA·Filed 2010·Granted Jan 15, 2013·10 cites·23 claims
- 2181US8779156B2Analogues for the treatment or prevention of flavivirus infectionsVERTEX PHARMA·Filed 2012·Granted Jul 15, 2014·7 cites·27 claims
- 2279US11623924B2Modulators of alpha-1 antitrypsinVERTEX PHARMA·Filed 2019·Granted Apr 11, 2023·3 cites·15 claims
- 2377US2021236505A1Substituted quinoxaline dna-pk inhibitorsVERTEX PHARMA·Filed 2021·Application pending·0 cites
- 2476US11813267B2DNA-PK inhibitorsVERTEX PHARMA·Filed 2020·Granted Nov 14, 2023·0 cites·19 claims
- 2576US11021465B2DNA-PK inhibitorsVERTEX PHARMA·Filed 2019·Granted Jun 1, 2021·0 cites·22 claims
- 2675US11008305B2DNA-PK inhibitorsVERTEX PHARMA·Filed 2019·Granted May 18, 2021·0 cites·20 claims
- 2769US8765731B2Benzimidazole analogues for the treatment or prevention of flavivirus infectionsVERTEX PHARMA·Filed 2012·Granted Jul 1, 2014·1 cites·22 claims
- 2869US2018311254A1Dna-pk inhibitorsVERTEX PHARMA·Filed 2018·Application pending·0 cites
- 2968US2023265080A1Modulators of alpha-1 antitrypsinVERTEX PHARMA·Filed 2023·Application pending·0 cites
- 3064US2016354381A1Dna-pk inhibitorsObligated Assignee·Filed 2016·Application pending·0 cites
- 3161US2024368106A1Hydroxy and alkoxy coumarins as modulators of polrmtPRETZEL THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3261US2024391875A1Isoquinolinones and quinolinones as modulators of polrmtPRETZEL THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3361US2025326732A1Chromen-2-one modulators of polrmtPRETZEL THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3460US8912326B2Process of making gyrase and topoisomerase inhibitorsVERTEX PHARMA·Filed 2013·Granted Dec 16, 2014·0 cites·24 claims
- 3557US2024158404A1Modulators of alpha-1 antitrypsinVERTEX PHARMA·Filed 2023·Application pending·0 cites
- 3657US2014243257A1Benzimidazole analogues for the treatment or prevention of flavivirus infectionsVERTEX PHARMA·Filed 2014·Application pending·0 cites
- 3754US12502376B2Pyrano[4,3-b]indole derivatives as alpha-1-antitrypsin modulators for treating alpha-1-antitrypsin deficiency (AATD)VERTEX PHARMA·Filed 2021·Granted Dec 23, 2025·0 cites·33 claims
- 3853US2023159502A1Indole derivatives as alpha-1-antitrypsin modulators for treating alpha-1-antitrypsin deficiency (aatd)VERTEX PHARMA·Filed 2021·Application pending·0 cites
- 3953US2023339915A1Modulators of alpha-1 antitrypsinVERTEX PHARMA·Filed 2021·Application pending·0 cites
- 4053US2023159504A17- or 8-hydroxy-isoquinoline and 7- or 8-hydroxy-quinoline derivatives as alpha-1-antitrypsin modulators for treating alpha-1-antitrypsin deficiency (aatd)VERTEX PHARMA·Filed 2021·Application pending·0 cites
- 4152US2023159580A1Pyrrolo[2,3-f]indazole and 2,4,5,10-tetrazatricyclo[7.3.0.03,7]dodeca-1,3(7),5,8,11-pentaene derivatives as alpha-1-antitrypsin modulators for treating alpha-1-antitrypsin deficiency (aatd)VERTEX PHARMA·Filed 2021·Application pending·0 cites
- 4252US2023159521A11h-pyrazolo[4,3-g]isoquinoline and 1h-pyrazolo[4,3-g]quinoline derivatives as alpha-1-antitrypsin modulators for treating alpha-1-antitrypsin deficiency (aatd)VERTEX PHARMA·Filed 2021·Application pending·0 cites
- 4343US2013085150A1Analogues for the treatment or prevention of flavivirus infectionsPEREIRA OSWY Z·Filed 2012·Application pending·0 cites
- 4443US2013102629A1Analogues for the treatment or prevention of flavivirus infectionsVERTEX PHARMA·Filed 2012·Application pending·0 cites
- 4540US2013090364A1Analogues for the treatment or prevention of flavivirus infectionsVERTEX PHARMA·Filed 2012·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Simon Giroux files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →